Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Position Boosted by Geode Capital Management LLC

Geode Capital Management LLC boosted its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 13.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 272,696 shares of the company’s stock after buying an additional 32,365 shares during the quarter. Geode Capital Management LLC owned approximately 1.06% of Eton Pharmaceuticals worth $1,637,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the third quarter worth $90,000. Renaissance Technologies LLC boosted its holdings in Eton Pharmaceuticals by 63.8% in the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares during the period. Stonepine Capital Management LLC bought a new stake in Eton Pharmaceuticals during the second quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday. HC Wainwright upped their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday.

Eton Pharmaceuticals Stock Performance

ETON stock opened at $12.01 on Thursday. Eton Pharmaceuticals, Inc. has a 1 year low of $3.03 and a 1 year high of $15.00. The stock has a market capitalization of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38. The stock’s fifty day moving average is $11.57 and its two-hundred day moving average is $7.32.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.